Approval of a new antibiotic is a pretty rare occurrence these days, so a green light in the EU for a novel intravenous cephalosporin developed by AstraZeneca (AZ) is something of a cause for ...
The agreement includes the commercialization and development rights to the newly approved EU drug Zavicefta™ (ceftazidime-avibactam), the marketed agents Merrem™/Meronem™ (meropenem) and Zinforo™ ...
ZINFORO (CEFTAROLINE FOSAMIL) RECEIVES POSITIVE CHMP OPINION IN THE EUROPEAN UNION FOR THE TREATMENT OF PATIENTS WITH SERIOUS SKIN INFECTIONS OR COMMUNITY ACQUIRED PNEUMONIA AstraZeneca today ...
Encouraging new data of relevance to Global public health crisis, presented at 25 th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) AstraZeneca today presented positive ...
Good news flowed in at AstraZeneca (AZN) from Europe when the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (:EMA) recommended the approval of AstraZeneca’s ...
Anglo-Swedish drugs developer AstraZeneca said its Zinforo skin infection treatment has been given a positive verdict by the Committee for Medicinal Products for Human Use (CHMP). The CHMP's positive ...
EUROPEAN COMMISSION APPROVES ZINFOROTM (CEFTAROLINE FOSAMIL) FOR ADULT PATIENTS WITH SERIOUS SKIN INFECTIONS OR COMMUNITY ACQUIRED PNEUMONIA AstraZeneca today announced that the European Commission ...
Phase III Data presented at 24 th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) AstraZeneca has announced results from a Phase III comparator trial, which demonstrated ...
The portfolio in this agreement include approved antibiotics Merrem, Zinforo, and Zavicefta, as well as candidates in clinical development, ATM-AVI and CXL. AstraZeneca has agreed to sell its ...
Pfizer Inc. announced that it has completed the acquisition of the development and commercialization rights to AstraZeneca’s late-stage small molecule anti-infective business, primarily outside the ...
The agreement includes the commercialization and development rights to the newly approved EU drug Zavicefta™ (ceftazidime-avibactam), the marketed agents Merrem™/Meronem™ (meropenem) and Zinforo™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results